Based on its recent dialogue with the FDA, Atara Biotherapeutics (NASDAQ:ATRA) announces that it expects to initiate its Biologics License Application (BLA) seeking approval for T-cell immunotherapy tab-cel (tabelecleucel) for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in H2 2020.
Update: Shares are down 13% on average volume as investors react to the pivot on the filing. Management originally forecasted that an application in Europe would be first up, expected in 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.